Munogenics

Munogenics, Inc. is a biotechnology company focused on developing, testing, and licensing novel biological methods for treating and preventing malignant diseases in humans. In collaboration with researchers at Wake Forest University, the company is commercializing a proprietary cancer treatment platform known as GIFT (Granulocyte InFusion Therapy) and the CKA (Cancer Killing Activity) diagnostic test. The GIFT process utilizes non-manipulated human granulocytes transfused from cancer-resistant donors to cancer-susceptible recipients to destroy a wide range of lethal cancers. The CKA test is designed to measure an individual's susceptibility or resistance to cancer and to identify eligible high-activity donors for the GIFT process.